Janux Therapeutics Stock Beneish M Score

JANX Stock  USD 29.94  0.49  1.61%   
This module uses fundamental data of Janux Therapeutics to approximate the value of its Beneish M Score. Janux Therapeutics M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out Janux Therapeutics Piotroski F Score and Janux Therapeutics Altman Z Score analysis.
For more information on how to buy Janux Stock please use our How to Invest in Janux Therapeutics guide.
  
At this time, Janux Therapeutics' Net Debt To EBITDA is fairly stable compared to the past year. Debt To Equity is likely to rise to 0.02 in 2025, whereas Short and Long Term Debt Total is likely to drop slightly above 17 M in 2025. At this time, Janux Therapeutics' Current Ratio is fairly stable compared to the past year. Tangible Book Value Per Share is likely to rise to 19.98 in 2025, whereas Free Cash Flow Yield is likely to drop (0.02) in 2025.
At this time, Janux Therapeutics' M Score is unavailable. The earnings manipulation may begin if Janux Therapeutics' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Janux Therapeutics executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Janux Therapeutics' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-2.58
Beneish M Score - Unavailable
Elasticity of Receivables

1.66

Focus
Asset Quality

1.0

Focus
Expense Coverage

1.94

Focus
Gross Margin Strengs

1.11

Focus
Accruals Factor

1.94

Focus
Depreciation Resistance

1.0

Focus
Net Sales Growth

0.54

Focus
Financial Leverage Condition

0.91

Focus

Janux Therapeutics Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Janux Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Total Assets1.1 B1.1 B
Sufficiently Up
Slightly volatile
Total Current Assets1.1 BB
Sufficiently Up
Slightly volatile
Non Current Assets Total17.2 M27.9 M
Way Down
Slightly volatile
Property Plant Equipment8.6 M8.1 M
Sufficiently Up
Slightly volatile
Depreciation And Amortization2.4 M2.2 M
Sufficiently Up
Slightly volatile
Selling General Administrative43.1 M41 M
Sufficiently Up
Slightly volatile
Total Current Liabilities12.4 M17.5 M
Way Down
Slightly volatile
Non Current Liabilities Total19 M21.3 M
Fairly Down
Slightly volatile
Short Term Debt1.3 M1.7 M
Way Down
Slightly volatile
Gross Profit Margin0.970.87
Moderately Up
Slightly volatile

Janux Therapeutics Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Janux Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Janux Therapeutics in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Janux Therapeutics' degree of accounting gimmicks and manipulations.

About Janux Therapeutics Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation And Amortization

2.36 Million

At this time, Janux Therapeutics' Depreciation And Amortization is fairly stable compared to the past year.

Janux Therapeutics Earnings Manipulation Drivers

Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as Janux Therapeutics. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
202020212022202320242025 (projected)
Net Receivables8M200K700K2.2M2.0M1.8M
Total Revenue380K3.6M8.6M8.1M10.6M5.7M
Total Assets16.2M379.8M364.0M380.4M1.1B1.1B
Total Current Assets16.1M377.0M332.4M349.2M1.0B1.1B
Net Debt(7.8M)(35.4M)(26.1M)5.3M(407.6M)(387.2M)
Short Term Debt751K388K1.5M1.5M1.7M1.3M
Operating Income(4.8M)(32.9M)(67.1M)(73.0M)(98.8M)(93.9M)

Janux Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Janux Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Janux Therapeutics' managers, analysts, and investors.
Environmental
Governance
Social

About Janux Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Janux Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Janux Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Janux Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Janux Stock Analysis

When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.